Increased serum IgM can be mistaken for disease progression, leading to a drug change, whereas a blockage in IgM secretion out of proportion to the tumor load lends to underestimating the posttreatment disease burden, missing the disease progression in some instances. Here, CD40LG is linked to neoplasm.